Topical chemotherapy for actinic keratosis and nonmelanoma skin cancer: Current options and future perspectives;Tratamiento quimioterápico tópico de la queratosis actínica y el cáncer cutáneo no melanoma: Situación actual y perspectivas

Actas Dermo-Sifiliograficas

Volumn 98, Issue 8, 2007, Pages 556-562

  Barrera Vigo, María Victoria ^a   Herrera, E ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Actinic keratosis; Nonmelanoma skin cancer; Topical treatment

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; RETINOIC ACID; RETINOID; TOPICAL AGENT;

ACTINIC KERATOSIS; ANTIBIOTIC THERAPY; BASAL CELL CARCINOMA; CHEMOTHERAPY; CORTICOSTEROID THERAPY; DRUG MECHANISM; HUMAN; PHOTODYNAMIC THERAPY; PRECANCER; REVIEW; SQUAMOUS CELL CARCINOMA; TOPICAL TREATMENT; TREATMENT OUTCOME;

EID: 35349012586     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(07)70133-3     Document Type: Article

References (33)

1. Jorizzo J, Carney P, Ko W. Treatment options in the management of actinic keratosis. Cutis. 2004;74:9-17.
2. Graaf YGL, Euvrard S, Bavinck JNB. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg. 2004;30:656-61.
3. Campanelli A, Naldi L. A retrospective study of the effect of long-term topical application of retinaldehyde (0.05%) on the development of actinic keratosis. Dermatology. 2002;205:146-52.
4. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med. 1999;341:1767-8.
5. Xu H, Cheepala S, McCauley E, Coombes K, Xiao L, Fischer SM, et al. Chemoprevention of Skin Carcinogenesis by Phenylretinamides: Retinoid Receptor-Independent Tumor Suppression. Clinical Cancer Research. 2006;12: 969-79.
6. Lober B, Fenske N. Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma). Am J Clin Dermatol. 2004;5:395-401.
7. McGillis S, Fein H. Topical treatment strategies for non-melanoma skin cancer precursor lesions. Semin Cutan Med Surg. 2004;23:174-83.
8. Tutrone W, Saini R, Caglar S, Weinberg J, Crespo J. Topical therapy for actinic keratoses, I: 5-fluoracil and imiquimod. Cutis. 2003;71:365-70.
9. Silapunt S, Goldberg L, Alam M. Topical and light-based treatments for actinic keratoses. Semin Cutan Med Surg. 2003;22:162-70.
10. Russo G. Actinic keratoses, basal cell carcinoma and squamous cell carcinoma: uncommon treatments. Clin Dermatol. 2005;23:581-6.
11. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Austr J Dermatol. 2003;44:40-3.
12. Rosso J. New and emerging topical approaches for actinic keratoses. Cutis. 2003;72:273-9.
13. Lang P. Management of actinic keratoses. Comp Ther. 2003;29:108-14.
14. Rosso J. Imiquimod 5% cream in the treatment of cutaneous epithelial malignancy: optimal use and duration of therapy. Cosmetic Dermatol. 2005;18:661-5.
15. Jorizzo J. Current and novel treatment options for actinic keratosis. J Cutan Med Surg. 2005;8:13-21.
16. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Australasian multicentre trial group. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001;44:807-13.
17. Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlles study. J Am Acad Dermatol. 2002;47:390-8.
18. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722-33.
19. Falagas M, Angelousi A, Peppas G. Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2006;55:537-8.
20. Gupta A, Davey V, Mphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005;9:209-14.
21. Quirk C, Gebauer K, Owens M, Stampone P. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol. 2006;47:258-65.
22. Vidal D, Matias-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol. 2007;143:266-8.
23. Shumack S, Robison J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod for the treatment of nodular basal cell carcinoma. Arch Dermatol. 2002;138:1165-71.
24. Eklind J, Tartler U, Maschke J, Lidbrink P, Hengge UR. Imiquimod to treat different cancers of the epidermis. Dermatol Surg. 2003;29:890-6.
25. Micali G, Lacarrubba F, Nasca MR, De Pasquale R. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome. Clin Exp Dermatol. 2003;28:19-23.
26. Roseeuw D. The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum. Clin Exp Dermatol. 2003;28:30-2.
27. Ulrich C, Busch J, Meyer T, Nindl I, Schmook T, Sterry W, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol. 2006;155:451-4.
28. Rosso J. The use of topical imiquimod for the treatment of actinic keratosis: a status report. Cutis. 2005;76:241-8.
29. Braathen L, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol. 2007;56:125-43.
30. Pariser DM, Lowe NJ, Stewart DM, Jarrat MT, Lucky AV, Pariser RJ, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratois: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003;48:227-32.
31. Morton C, Horn M, Lehman J, Tack B, Bedane C, Tijoe M, et al. A 24-month update of a placebo controlled European study comparing MAL-PDT with cryotherapy and 5-fluoracil in patients with Bowen's disease. J Eur Acad Dermatol Venereol. 2005;19:237-8.
32. Tope WD, Menter A, El-Azhary RA, Lowe NJ, Jarrat M, Pariser DM, et al. Comparison of topical methyl aminolevulinate photodynamic therapy versus placebo photodynamic therapy in nodular BCC. J Eur Acad Dermatol Venereol. 2004;18:413-4.
33. Perrett CM, McGregor JM, Warwick P, Karran P, Leigh IM, Proby CM, et al. Treatment of post-trasplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol. 2007;156:320-8.